Questions relate to the image as well as to selected articles in JID, which are listed after the questions. Answers will be posted as supplementary material. We hope you enjoy this challenge.
Questions
1. A 20-year-old woman presents to the clinic complaining of this eruption (see image above), which has been present intermittently for two years. Which of the following statements is false regarding the pathophysiology of this disease?
- a. The severity of this eruption does not correlate with serum androgen levels.
- b. Individuals with complete androgen insensitivity are not affected by this disease.
- c. Estrogen in sufficient amounts is known to suppress sebum production.
- d. Sebum composition may be more important for the development of these lesions than the secreted amount.
- e. High linoleate levels have been observed in the skin surface lipids of these patients.
2. Paithankar et al. (2015) hypothesized that light-absorbing microparticles could be delivered into sebaceous glands, enabling local injury by optical pulses. They used a suspension of topically applied gold-coated silica microparticles exhibiting plasmon resonance with strong absorption at which of the following:
- a. 585 nm.
- b. 1720 nm.
- c. 1320 nm.
- d. 1450 nm.
- e. 800 nm.
3. To prove their hypothesis, Paithankar et al. performed ex vivo and in vivo animal skin studies followed by two independent prospective randomized controlled clinical trials in humans, which showed clinically and statistically significant improvement of inflammatory lesions following three treatments given 1–2 weeks apart. Which of the following is true regarding these studies?
- a. The damage to the sebaceous follicles caused a tattoo by releasing gold particles into the surrounding dermis.
- b. Cutaneous gold concentration returned to baseline level within 72 hours posttreatment.
- c. Treatment resulted in nonselective thermal injury in sebaceous follicles of swine and humans.
- d. Treatment did not result in damage to the adjacent epidermis and dermis.
- e. Efficacy and safety of this novel therapeutic modality were established in patients with Fitzpatrick skin type IV.
Answers are available as supplementary material online. http://dx.doi.org/10.1038/jid.2015.173
Topic Article
Questions 2 and 3 refer to the following article:
- Supplementary Information 1
Article info
Identification
Copyright
© 2015 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
37304-8&id=fx1.jpg){kind=link}